The function and mechanism of the JARID2/CCND1 axis in modulating glioma cell growth and sensitivity to temozolomide (TMZ)

References

• Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. 2015. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 17(Suppl 4):iv1–iv62. doi:10.1093/neuonc/nov189.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, De Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, et al. 2016. American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 18(Suppl 1):i1–i50. doi:10.1093/neuonc/nov297.
   PubMedGoogle Scholar
• Zanders ED, Svensson F, Bailey DS. 2019. Therapy for glioblastoma: is it working? Drug Discov Today. 24(5):1193–1201. doi:10.1016/j.drudis.2019.03.008.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al. 2014. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 370(8):699–708. doi:10.1056/NEJMoa1308573.
   PubMed Web of Science ®Google Scholar
• Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, et al. 2014. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 15(9):e395–403. doi:10.1016/S1470-2045(14)70011-7.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Kerby T, Calvert H. 2000. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 6(7):2585–2597.
   PubMed Web of Science ®Google Scholar
• Karachi A, Dastmalchi F, Mitchell DA, Rahman M. 2018. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol. 20(12):1566–1572. doi:10.1093/neuonc/noy072.
   PubMed Web of Science ®Google Scholar
• Hombach-Klonisch S, Mehrpour M, Shojaei S, Harlos C, Pitz M, Hamai A, Siemianowicz K, Likus W, Wiechec E, Toyota BD, et al. 2018. Glioblastoma and chemoresistance to alkylating agents: involvement of apoptosis, autophagy, and unfolded protein response. Pharmacol Ther. 184:13–41. doi:10.1061/j.pharmthera.2017.10.017.
   PubMed Web of Science ®Google Scholar
• Lu Y, Kwintkiewicz J, Liu Y, Tech K, Frady LN, Su Y-T, Bautista W, Moon SI, MacDonald J, Ewend MG, et al. 2017. Chemosensitivity of IDH1-Mutated Gliomas due to an impairment in PARP1-Mediated DNA repair. Cancer Res. 77(7):1709–1718. doi:10.1158/0008-5472.CAN-16-2773.
   PubMed Web of Science ®Google Scholar
• SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, LanXiao W, Fei Y. 2012. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 103(2):269–273. doi:10.1111/j.1349-7006.2011.02134.x.
   PubMed Web of Science ®Google Scholar
• Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, et al. 2010. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 75(17):1560–1566. doi:10.1212/WNL.0b013e3181f96282.
   PubMed Web of Science ®Google Scholar
• Lin L, Cai J, Tan Z, Meng X, Li R, Li Y, Jiang C. 2021. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma. Cancer Res Treat. 53(2):367–377. doi:10.4143/crt.2020.506
   Google Scholar
• Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ, Woodworth DC, Nghiemphu PL, Cloughesy TF, Ellingson BM. 2014. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol. 16(3):414–420. doi:10.1093/neuonc/not198
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. 2010. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 465(7300):966. doi:10.1038/nature09132.
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Yeoh KK, Tian Y-M, Hillringhaus L, Bagg EA, Rose NR, Leung IKH, Li XS, Woon ECY, Yang M, et al. 2011. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12(5):463–469. doi:10.1038/embor.2011.43.
   PubMed Web of Science ®Google Scholar
• Lu C, Thompson CB. 2012. Metabolic regulation of epigenetics. Cell Metab. 16(1):9–17. doi:10.1016/j.cmet.2012.06.001.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, Ito S, Yang C, Wang P, Xiao M-T, et al. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 19(1):17–30. doi:10.1016/j.ccr.2010.12.014.
   PubMed Web of Science ®Google Scholar
• Wang P, Wu J, Ma S, Zhang L, Yao J, Hoadley K, Wilkerson M, Perou C, Guan K-L, Ye D, et al. 2015. Oncometabolite D-2-Hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents. Cell Rep. 13(11):2353–2361. doi:10.1016/j.celrep.2015.11.029.
   PubMed Web of Science ®Google Scholar
• Yamashita AS, Da Costa Rosa M, Borodovsky A, Festuccia WT, Chan T, Riggins GJ. 2019. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro Oncol. 21(2):189–200. doi:10.1093/neuonc/noy146.
   PubMed Web of Science ®Google Scholar
• Celik H, Koh WK, Kramer AC, Ostrander EL, Mallaney C, Fisher DAC, Xiang J, Wilson WC, Martens A, Kothari A, et al. 2018. JARID2 functions as a tumor suppressor in myeloid neoplasms by repressing self-renewal in hematopoietic progenitor cells. Cancer Cell. 34(5):741–756 e8. doi:10.1016/j.ccell.2018.10.008.
   PubMed Web of Science ®Google Scholar
• Li G, Margueron R, Ku M, Chambon P, Bernstein BE, Reinberg D. 2010. Jarid2 and PRC2, partners in regulating gene expression. Genes Dev. 24(4):368–380. doi:10.1101/gad.1886410.
   Google Scholar
• Herz HM, Shilatifard A. 2010. The JARID2-PRC2 duality. Genes Dev. 24(9):857–861. doi:10.1101/gad.1921610.
   PubMed Web of Science ®Google Scholar
• Cifuentes-Rojas C, Hernandez A, Sarma K, Lee J. 2014. Regulatory interactions between RNA and polycomb repressive complex 2. Mol Cell. 55(2):171–185. doi:10.1016/j.molcel.2014.05.009.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Q, Cui Y, Liu ZY, Zhao W, Wang CL, Dong Y, Hou L, Hu G, Luo C, et al. 2012. Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells. J Neurooncol. 106(3):473–484. doi:10.1007/s11060-011-0692-4.
   PubMed Web of Science ®Google Scholar
• Arcella A, Oliva MA, Staffieri S, Aalberti S, Grillea G, Madonna M, Bartolo M, Pavone L, Giangaspero F, Cantore G, et al. 2015. In vitro and in vivo effect of human lactoferrin on glioblastoma growth. J Neurosurg. 123(4):1026–1035. doi:10.3171/2014.12.JNS14512.
   PubMed Web of Science ®Google Scholar
• Shirato H, Ogawa S, Nakajima K, Inagawa M, Kojima M, Tachibana M, Shinkai Y, Takeuchi T. 2009. A jumonji (Jarid2) protein complex represses cyclin D1 expression by methylation of histone H3-K9. J Biol Chem. 284(2):733–739. doi:10.1074/jbc.M804994200.
   PubMed Web of Science ®Google Scholar
• Su C-L, Deng T-R, Shang Z, Xiao Y. 2015. JARID2 inhibits leukemia cell proliferation by regulating CCND1 expression. Int J Hematol. 102(1):76–85. doi:10.1007/s12185-015-1797-x.
   PubMed Web of Science ®Google Scholar
• Nakajima K, Inagawa M, Uchida C, Okada K, Tane S, Kojima M, Kubota M, Noda M, Ogawa S, Shirato H, et al. 2011. Coordinated regulation of differentiation and proliferation of embryonic cardiomyocytes by a jumonji (Jarid2)-cyclin D1 pathway. Development. 138(9):1771–1782. doi:10.1242/dev.059295.
   PubMed Web of Science ®Google Scholar
• Mayer RL, Schwarzmeier JD, Gerner MC, Bileck A, Mader JC, Meier-Menches SM, Gerner SM, Schmetterer KG, Pukrop T, Reichle A, et al. 2018. Proteomics and metabolomics identify molecular mechanisms of aging potentially predisposing for chronic lymphocytic leukemia. Mol Cell Proteomics. 17(2):290–303. doi:10.1074/mcp.RA117.000425.
   PubMed Web of Science ®Google Scholar
• Slezak-Prochazka I, Kluiver J, de Jong D, Smigielska-Czepiel K, Kortman G, Winkle M, Rutgers B, Koerts J, Visser L, Diepstra A, et al. 2016. Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma. Oncotarget. 7(3):2391–2400. doi:10.18632/oncotarget.6165.
   PubMedGoogle Scholar
• Puda A, Milosevic JD, Berg T, Klampfl T, Harutyunyan AS, Gisslinger B, Rumi E, Pietra D, Malcovati L, Elena C, et al. 2012. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol. 87(3):245–250. doi:10.1002/ajh.22257.
   PubMed Web of Science ®Google Scholar
• Jiang T, Nam D-H, Ram Z, Poon W-S, Wang J, Boldbaatar D, Mao Y, Ma W, Mao Q, You Y, et al. 2021. Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 499:60–72. doi:10.1016/j.canlet.2020.10.050.
   PubMed Web of Science ®Google Scholar
• Han B, Meng X, Wu P, Li Z, Li S, Zhang Y, Zha C, Ye Q, Jiang C, Cai J, et al. 2020. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma. Theranostics. 10(7):3351–3365. doi:10.7150/thno.41219.
   PubMed Web of Science ®Google Scholar
• Wen Z-P, Zeng W-J, Chen Y-H, Li H, Wang J-Y, Cheng Q, Yu J, Zhou -H-H, Liu -Z-Z, Xiao J, et al. 2019. Knockdown ATG4C inhibits gliomas progression and promotes temozolomide chemosensitivity by suppressing autophagic flux. J Exp Clin Cancer Res. 38(1):298. doi:10.1186/s13046-019-1287-8.
   PubMed Web of Science ®Google Scholar
• Bao Z, Chen L, Guo S. 2019. Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma. J Cell Biochem. 120(6):10205–10214. doi:10.1002/jcb.28305.
   PubMed Web of Science ®Google Scholar
• Li M, Liang RF, Wang X, Mao Q, Liu YH. 2017. BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-kappaB/MGMT signaling pathway. Oncol Lett. 14(6):6597–6603. doi:10.3892/ol.2017.7034.
   PubMed Web of Science ®Google Scholar
• Cao Y, Li X, Kong S, Shang S, Qi Y. 2020. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells. J Cell Mol Med. 24(9):5135–5145. doi:10.1111/jcmm.15156.
   PubMed Web of Science ®Google Scholar
• Sumorek-Wiadro J, Zając A, Bądziul D, Langner E, Skalicka-Woźniak K, Maciejczyk A, Wertel I, Rzeski W, Jakubowicz-Gil J. 2020. Coumarins modulate the anti-glioma properties of temozolomide. Eur J Pharmacol. 881:173207. doi:10.1016/j.ejphar.2020.173207.
   PubMed Web of Science ®Google Scholar
• Wu Y, Dong L, Bao S, Wang M, Yun Y, Zhu R. 2016. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways. Biomed Pharmacother. 84:462–469. doi:10.1016/j.biopha.2016.09.051.
   PubMed Web of Science ®Google Scholar
• Shao N, Mao J, Xue L, Wang R, Zhi F, Lan Q. 2019. Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma. J Neurooncol. 141(2):277–288. doi:10.1007/s11060-018-03043-5.
   PubMed Web of Science ®Google Scholar
• Liu X, Kang J, Liu F, Wen S, Zeng X, Liu K, Luo Y, Ji X, Zhao S. 2016. Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis. Tumour Biol. 37(5):6323–6330. doi:10.1007/s13277-015-4503-y.
   PubMedGoogle Scholar
• Chen R, Liu H, Cheng Q, Jiang B, Peng R, Zou Q, Yang W, Yang X, Wu X, Chen Z, et al. 2016. MicroRNA-93 promotes the malignant phenotypes of human glioma cells and induces their chemoresistance to temozolomide. Biol Open. 5(6):669–677. doi:10.1242/bio.015552.
   PubMed Web of Science ®Google Scholar
• Ma L, Li J. 2020. MicroRNA-519d-3p inhibits cell proliferation and cell cycle G1/S transition in glioma by targeting CCND1. Biosci Biotechnol Biochem. 84(2):297–304. doi:10.1080/09168451.2019.1682510.
   PubMed Web of Science ®Google Scholar